Of the two previous studies examining NLR and HER2+ breast cancer [30,33], one found that NLR correlated with PFS and OS in patients who received T-DM1 [30], and the second study found that improved PFS was not significantly associated with NLR but absolute lymphocyte count ≥1500/μL. Here, ERBB2 is linked to breast cancer.